These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3286439)

  • 21. Cognitive improvement during Tolcapone treatment in Parkinson's disease.
    Gasparini M; Fabrizio E; Bonifati V; Meco G
    J Neural Transm (Vienna); 1997; 104(8-9):887-94. PubMed ID: 9451720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease.
    Factor SA; Molho ES; Feustel PJ; Brown DL; Evans SM
    Clin Neuropharmacol; 2001; 24(5):295-9. PubMed ID: 11586115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
    Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
    Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients.
    Barone P; Santangelo G; Morgante L; Onofrj M; Meco G; Abbruzzese G; Bonuccelli U; Cossu G; Pezzoli G; Stanzione P; Lopiano L; Antonini A; Tinazzi M
    Eur J Neurol; 2015 Aug; 22(8):1184-91. PubMed ID: 25962410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial.
    Weintraub D; Hauser RA; Elm JJ; Pagan F; Davis MD; Choudhry A;
    Mov Disord; 2016 May; 31(5):709-14. PubMed ID: 27030249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hepatitis probably caused by exifone (Adlone)].
    Larrey D; Biclet P; Razafimahaleo A; Degott C; Devergie B; Babany G; Mosnier JF; Scoazec JY; Feldmann G; Pessayre D
    Gastroenterol Clin Biol; 1989 Apr; 13(4):397-400. PubMed ID: 2737393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aggravation of Parkinson's disease by cinnarizine.
    Martí Massó JF; Obeso JA; Carrera N; Martínez-Lage JM
    J Neurol Neurosurg Psychiatry; 1987 Jun; 50(6):804-5. PubMed ID: 3302112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa.
    Leeman AL; O'Neill CJ; Nicholson PW; Deshmukh AA; Denham MJ; Royston JP; Dobbs RJ; Dobbs SM
    Br J Clin Pharmacol; 1987 Nov; 24(5):637-43. PubMed ID: 3325092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychopharmacological profile of the new cognition enhancing agent exifone in the mouse.
    Porsolt RD; Lenègre A; Avril I; Lancrenon S; Stéru L; Doumont G
    Arzneimittelforschung; 1987 Apr; 37(4):388-93. PubMed ID: 2886129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A controlled trial of piracetam in intellectually impaired patients with Parkinson's disease.
    Sano M; Stern Y; Marder K; Mayeux R
    Mov Disord; 1990; 5(3):230-4. PubMed ID: 2388639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.
    Aarsland D; Laake K; Larsen JP; Janvin C
    J Neurol Neurosurg Psychiatry; 2002 Jun; 72(6):708-12. PubMed ID: 12023410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of tolcapone on the haemodynamic effects and tolerability of desipramine.
    Jorga KM; Fotteler B; Modi M; Rabbia M
    Eur Neurol; 2000; 44(2):94-103. PubMed ID: 10965161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease.
    Yoritaka A; Kawajiri S; Yamamoto Y; Nakahara T; Ando M; Hashimoto K; Nagase M; Saito Y; Hattori N
    Parkinsonism Relat Disord; 2015 Aug; 21(8):911-6. PubMed ID: 26054881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease.
    Entacapone to Tolcapone Switch Study Investigators
    Mov Disord; 2007 Jan; 22(1):14-9. PubMed ID: 17089403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial.
    Antonini A; Bauer L; Dohin E; Oertel WH; Rascol O; Reichmann H; Schmid M; Singh P; Tolosa E; Chaudhuri KR
    Eur J Neurol; 2015 Oct; 22(10):1400-7. PubMed ID: 26095948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group.
    Hauser RA; Molho E; Shale H; Pedder S; Dorflinger EE
    Mov Disord; 1998 Jul; 13(4):643-7. PubMed ID: 9686768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA; Fahn S; Jankovic J; Pourcher E; Hsu A; O'Connell M; Kell S; Gupta S;
    Parkinsonism Relat Disord; 2014 Feb; 20(2):142-8. PubMed ID: 24055014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease.
    Limousin P; Pollak P; Gervason-Tournier CL; Hommel M; Perret JE
    Lancet; 1993 Jun; 341(8860):1605. PubMed ID: 8099689
    [No Abstract]   [Full Text] [Related]  

  • 40. Low-dose bromocriptine therapy in Parkinson's disease: double-blind, placebo-controlled study.
    Staal-Schreinemachers AL; Wesseling H; Kamphuis DJ; vd Burg W; Lakke JP
    Neurology; 1986 Feb; 36(2):291-3. PubMed ID: 3511405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.